BioTime Buys Geron's Stem Cell Assets, Including hESC Clinical Trial
Geron Corp., which pioneered the first clinical trial of an hESC therapy, today sold its stem cell business to another San Francisco Bay Area firm whose two top executives were once CEOs at Geron.
Michael West
BioTime photoThe total value of the complex deal was not clear from the public statements released by Geron and the acquiring firm, BioTime, Inc., …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.